Key result
Oral immunization of mother mice with 160 μg of recombinant EV71 VP1 formulated with chitosan conferred a 30% survival rate in their neonatal offspring against a lethal EV71 challenge, compared to 0% in the control group.
Why the study?
Does oral immunization with recombinant VP1 protein formulated with chitosan induce immune responses and protect against lethal EV71 challenge in mice?
Does oral immunization with recombinant VP1 protein formulated with chitosan induce immune responses and protect against lethal EV71 challenge in mice?
Absolute Event Rate: 30% vs 0%
Absolute Risk Reduction: 30%
Oral immunization with rVP1 formulated with chitosan induces broad-spectrum immune responses and provides partial protection against lethal EV71 challenge in a mouse model.
Partial neonatal protection in mice supports maternal immunization research; leaves open translation to human EV71 prevention.
BACKGROUND: Enterovirus 71 (EV71) is the etiologic agent of hand-foot-and-mouth disease (HFMD) in the Asia-Pacific region, Many strategies have been applied to develop EV71 vaccines but no vaccines are currently available. Mucosal immunization of the VP1, a major immunogenic capsid protein of EV71, may be an alternative way to prevent EV71 infection. RESULTS: In this study, mucosal immunogenicity and protect function of recombinant VP1 protein (rVP1) in formulation with chitosan were tested and assessed in female ICR mouse model. The results showed that the oral immunization with rVP1 induced VP1-specific IgA antibodies in intestine, feces, vagina, and the respiratory tract and serum-specific IgG and neutralization antibodies in vaccinated mice. Splenocytes from rVP1-immunized mice induced high levels of Th1 (cytokine IFN-γ), Th2 (cytokine IL-4) and Th3 (cytokine TGF-β) type immune responses after stimulation. Moreover, rVP1-immunized mother mice conferred protection (survival rate up to 30%) on neonatal mice against a lethal challenge of 103 plaque-forming units (PFU) EV71. CONCLUSIONS: These data indicated that oral immunization with rVP1 in formulation with chitosan was effective in inducing broad-spectrum immune responses and might be a promising subunit vaccine candidate for preventing EV71 infection.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2014) studied Enterovirus 71 (EV71) infection (n=64). Recombinant EV71 VP1 protein formulated with chitosan vs. PBS (Placebo) was evaluated on Survival rate of neonatal mice against lethal EV71 challenge. Oral immunization of mother mice with 160 μg of recombinant EV71 VP1 formulated with chitosan conferred a 30% survival rate in their neonatal offspring against a lethal EV71 challenge, compared to 0% in the control group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: